Evidence map›Paper›PMID 19010365›Full record

ArticleNeurochemistry international2009

Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2.

M G Morgese, T Cassano, S Gaetani, T Macheda, L Laconca, P Dipasquale, L Ferraro, T Antonelli, V Cuomo, A Giuffrida

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurochemistry international, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 44 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. The endocannabinoid system: a putative role in neurodegenerative diseases.International journal of high risk behaviors & addiction · 2013
    Review
  10. Article
  11. New insights on endocannabinoid transmission in psychomotor disorders.Progress in neuro-psychopharmacology & biological psychiatry · 2012
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

M G MorgeseDepartment of Biomedical Sciences, University of Foggia, Italy.
T Cassano
S Gaetani
T Macheda
L Laconca
P Dipasquale
L Ferraro
T Antonelli
V Cuomo
A Giuffrida
University of Foggia · ITSapienza University of Rome · ITUniversity of Ferrara · ITThe University of Texas Health Science Center at San Antonio · US

Funding

Role of Endocannabinoids in Levodopa-Induced DyskinesiasR01NS050401 · NINDS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI GIUFFRIDA, ANDREA · 2005 to 2012
$2.3M
NINDS NIH HHS NS 050401-04NINDS NIH HHS R01 NS050401
6 · The paper itself

Abstract

Chronic use of levodopa, the most effective treatment for Parkinson's disease, causes abnormal involuntary movements named dyskinesias, which are linked to maladaptive changes in plasticity and disturbances of dopamine and glutamate neurotransmission in the basal ganglia. Dyskinesias can be modeled in rats with unilateral 6-hydroxydopamine lesions by repeated administration of low doses of levodopa (6 mg/kg, s.c.). Previous studies from our lab showed that sub-chronic treatment with the cannabinoid agonist WIN55,212-2 attenuates levodopa-induced dyskinesias at doses that do not interfere with physiological motor function. To investigate the neurochemical changes underlying WIN55,212-2 anti-dyskinetic effects, we used in vivo microdialysis to monitor extracellular dopamine and glutamate in the dorsal striatum of both the hemispheres of freely moving 6-hydroxydopamine-treated, SHAM-operated and intact rats receiving levodopa acutely or chronically (11 days), and studied how sub-chronic WIN55,212-2 (1 injection x 3 days, 20 min before levodopa) affected these neurochemical outputs. Our data indicate that: (1) the 6-hydroxydopamine lesion decreases dopamine turnover in the denervated striatum; (2) levodopa injection reduces extracellular glutamate in the side ipsilateral to the lesion of dyskinetic rats; (3) sub-chronic WIN55,212-2 prevents levodopa-induced glutamate volume transmission unbalances across the two hemispheres; and (4) levodopa-induced dyskinesias are inversely correlated with glutamate levels in the denervated striatum. These data indicate that the anti-dyskinetic properties of WIN55,212-2 are accompanied by changes of dopamine and glutamate outputs in the two brain hemispheres of 6-hydroxydopamine-treated rats.

Indexed as

AmphetamineAnimalsBenzoxazinesCalcium Channel BlockersCannabinoidsCorpus StriatumDopamineDyskinesiasGlutamineHomovanillic AcidLevodopaMaleMorpholinesNaphthalenesOxidopamineRats(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanoneAmphetamineBenzoxazinesCalcium Channel BlockersCannabinoidsDopamineGlutamineHomovanillic AcidLevodopaMorpholinesNaphthalenesOxidopamine

Identifiers

PMID19010365
PMCPMC2657321
OpenAlexW2109209155

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.